The US Food and Drug Administration confirmed on Friday that toxic cough syrups linked to children's deaths in India had not been shipped to the United States.
The World Health Organization has said India has a "regulatory gap" in screening locally sold syrup medicines.
The US FDA said it was aware of news reports of devastating, ongoing diethylene glycol and ethylene glycol contamination in children's cough and cold medicine in India.
Indian authorities advised the public to avoid two more brands of cough syrup on Wednesday following the deaths of 17 children under age five, linked to a toxic ingredient.
The children died in India over the past month after consuming cough medicine containing toxic diethylene glycol in quantities nearly 500 times the permissible limit, officials said. The deaths were all linked to the Coldrif medicine brand, which was banned after a test confirmed the presence of the chemical on October 2.
India's health authority, the Central Drugs Standard Control Organization, informed the US regulator that these products were not exported from India to any other country, the FDA said.
The FDA also said it remains vigilant to prevent contaminated drugs from entering the US and asked manufacturers to ensure that drugs marketed in the US are safe and of the highest quality.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)